Cadrenal Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Cash & Equivalents	3.86	10.02	8.4	0.03
Cash & Short-Term Investments	3.86	10.02	8.4	0.03
Cash Growth	-11.54%	19.23%	25685.61%	-
Other Receivables	0.01	0.04	0.04	-
Receivables	0.01	0.04	0.04	-
Prepaid Expenses	0.12	0.04	0.05	0.02
Other Current Assets	0.09	0.01	-	0.67
Total Current Assets	4.08	10.11	8.49	0.73
Property, Plant & Equipment	0.01	0.01	0.02	0.04
Other Long-Term Assets	0	0	0	0.01
Total Assets	4.09	10.12	8.52	0.78
Accounts Payable	0.61	1.5	0.17	0.4
Accrued Expenses	0.74	1.18	0.64	0.86
Short-Term Debt	-	-	-	0.04
Current Portion of Leases	-	-	0.02	0.02
Total Current Liabilities	1.35	2.68	0.83	1.33
Long-Term Debt	-	-	-	0.55
Long-Term Leases	-	-	-	0.02
Other Long-Term Liabilities	-	-	-	4.42
Total Liabilities	1.35	2.68	0.83	6.33
Common Stock	0	0	0	0.01
Additional Paid-In Capital	38.65	33.16	22.76	1.15
Retained Earnings	-35.92	-25.72	-15.07	-6.71
Shareholders' Equity	2.73	7.44	7.69	-5.55
Total Liabilities & Equity	4.09	10.12	8.52	0.78
Total Debt	-	-	0.02	0.64
Net Cash (Debt)	3.86	10.02	8.38	-0.61
Net Cash Growth	-11.50%	19.53%	-	-
Net Cash Per Share	2.20	8.21	9.32	-1.16
Filing Date Shares Outstanding	2.08	1.88	1.07	0.78
Total Common Shares Outstanding	2.06	1.78	0.87	0.55
Working Capital	2.73	7.43	7.67	-0.61
Book Value Per Share	1.33	4.17	8.86	-10.16
Tangible Book Value	2.73	7.44	7.69	-5.55
Tangible Book Value Per Share	1.33	4.17	8.86	-10.16

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q